MORAb-009

DRUG3 trials

Sponsors

Morphotek, Eisai Co., Ltd.

Conditions

CancerMesothelin-positiveMesotheliomaNon-Small Cell Lung CancerOvarian CancerPancreatic Cancer

Phase 1

A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer

CompletedNCT00325494

MorphotekMesothelioma, Non-Small Cell Lung Cancer, Ovarian Cancer +1

Start: 2006-05-31End: 2008-09-30Updated: 2014-07-17

A Study of MORAb-009 in Patients With Solid Tumor

CompletedNCT01018784

Eisai Co., Ltd.Cancer, Mesothelin-positive

Start: 2009-11-30End: 2013-02-28Updated: 2016-01-21

Phase 2

An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer

CompletedNCT00570713

MorphotekPancreatic Cancer

Start: 2007-12-31End: 2009-12-31Updated: 2015-09-09

Related Papers

Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors.

2014-12-1234 citations